Calls for papers
-
Frazier Life Sciences has launched a new company called AirNexis Therapeutics, which will develop inhaled suspension and dry powder formulations of HSK39004, a dual PDE3/4 inhibitor for the treatment of COPD that it has licensed… Read more . . .
-
Kinaset Therapeutics announced that it has raised $103 million in a Series B financing, with proceeds to be used for development of its KN-002 frevecitinib DPI for the treatment of asthma. The financing was led… Read more . . .
-
Nocion Therapeutics said that it has raised an additional $23 million, expanding a Series B financing that raised $62 million in 2024 for development of the company’s taplucainium DPI for the treatment of chronic cough.… Read more . . .
-
Agomab Therapeutics has announced interim results from a Phase 1 study of AGMB-447 inhaled ALK5 inhibitor that was initiated in 2023. The data from the SAD/MAD portion of the study in 108 healthy participants found… Read more . . .
-
Krystal Biotech has announced results from the highest dose cohort of its Phase 1 CORAL-1 trial of KB407 gene therapy that confirm CFTR expression in 6 of 7 cystic fibrosis patients who received 4 administrations… Read more . . .
-
Pulmocide has announced the termination of the Opera-T Phase 3 study of opelconazole inhalation suspension in patients with invasive pulmonary aspergillosis. According to the company, an interim analysis found that patients receiving opelconazole had poorer… Read more . . .
-
Florida-based inhaled drug developer Transpire Bio has announced the initiation of a Phase 1 trial of a synthetic inhaled cannabidiol formulation, which the company is developing for Parkinson’s disease psychosis and for other central nervous… Read more . . .
-
Milestone Pharmaceuticals announced that the European Medicines Agency has accepted the company’s marketing application for its etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT), with a decision expected in early 2027. If approved, the… Read more . . .
-
GH Research announced that the FDA has lifted a clinical hold on the company’s IND for GH001 inhaled mebufotenin (5-MeO-DMT) for the treatment of treatment-resistant depression and that initiation of a Phase 3 trial is… Read more . . .
-
According to SoftOx Solutions, the Danish Medicines Agency has approved the company’s application for a Phase 2a trial of SoftOx hypochlorous acid inhalation solution in healthy volunteers and in patients with cystic fibrosis. SoftOx announced… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland